SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-061910
Filing Date
2021-11-24
Accepted
2021-11-24 15:06:39
Documents
4
Period of Report
2021-11-24

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea151384-6k_biondvax.htm 6-K 9687
2 PRESS RELEASE ea151384-6kex99i_biondvax.htm EX-99.1 16452
3 GRAPHIC image_002.jpg GRAPHIC 6294
4 GRAPHIC image_001.gif GRAPHIC 187
  Complete submission text file 0001213900-21-061910.txt   36435
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 211445605
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences